Tenthoff Analyst Maintains Buy Rating for Arrowhead Pharmaceuticals

Summary

Tenthoff, an analyst with a -13.5% average return and a 33.33% success rate, maintains a Buy rating on Arrowhead Pharmaceuticals with a $36.00 price target, indicating a 12.32% upside. H.C. Wainwright also maintains a Buy rating with a $80.00 price target.Tip Ranks

Impact Analysis

So basically, Tenthoff’s buy rating on Arrowhead Pharmaceuticals feels like a classic case of ‘do as I say, not as I do.’ With an average return of -13.5% and a success rate of just 33.33% on his stock picks, Tenthoff’s endorsement might not carry the weight it should Tip Ranks. The market consensus is a Moderate Buy with a $36.00 target, but H.C. Wainwright’s $80.00 target suggests there’s a belief in significant upside potential Tip Ranks. The technicals are interesting too—MACD and moving averages indicate a bullish trend, but the stock is nearing resistance levels, which could trigger profit-taking . The real play here might be in the divergence between analyst optimism and Tenthoff’s track record. If the market is overly skeptical due to his past performance, there could be an opportunity if Arrowhead delivers on its pipeline promises.